Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En tidlig gennemførlighedsundersøgelse, der evaluerer sikkerheden og effektiviteten af ​​det laminære venstre atrielle vedhængs lukkesystem hos personer med ikke-valvulær atrieflimren

14. oktober 2026 opdateret af: Jaguar LAA, Inc.

This is an early feasibility study is to evaluate the safety and effectiveness of the Laminar Left Atrial Appendage Closure System to treat patients with non-valvular atrial fibrillation that cannot take, or a have a reason to seek an alternative, to anticoagulant medications.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Intervention / Behandling

Detaljeret beskrivelse

Left atrial appendage closure (LAAC) is an approved therapy for stroke prevention in atrial fibrillation patients who are recommended for chronic oral anticoagulation therapy (OAC), but are non-eligible or have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulants in accordance with evidence-based decision-making criteria and current scientific guidelines.

The objective of this study is to evaluate the safety and effectiveness of the Laminar Left Atrial Appendage Closure System to treat patients with non-valvular atrial fibrillation who are deemed appropriate for LAAC to reduce the risk of stroke and systemic embolism.

Patients will be followed for 5 years after the procedure.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

58

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Arizona
      • Tucson, Arizona, Forenede Stater, 85712
        • Tucson Medical Center
    • Arkansas
      • Jonesboro, Arkansas, Forenede Stater, 72401
        • St. Bernard's Heart & Vascular
    • California
      • La Jolla, California, Forenede Stater, 92037
        • Scripps Health
      • Sacramento, California, Forenede Stater, 95817
        • Univeristy of California Davis Health
      • Thousand Oaks, California, Forenede Stater, 91360
        • Cardiovascular Institute Los Robles Hospital and Medical Center
    • New York
      • New York, New York, Forenede Stater, 10032
        • Columbia University Medical Center
      • New York, New York, Forenede Stater, 10029
        • Icahn School of Medicine at Mt. Sinai

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Documented non-valvular atrial fibrillation (AF), defined as AF (paroxysmal, persistent, or permanent) in the absence of moderate-to-severe mitral stenosis or a mechanical heart valve
  • Participant greater than or equal to (>=)18 years old
  • CHA2DS2-VASc score >=2 in men and >= 3 in women
  • Participant is recommended for chronic oral anticoagulation therapy (OAC) but is not eligible or has an appropriate rationale to seek a non-pharmacologic alternative to chronic OAC
  • Participant deemed appropriate for LAA closure by the Site Heart Team using an evidenced based decision-making tool
  • Participant eligible for the protocol-specified post-procedural antithrombotic regimen
  • Participant or Legally Authorized Representative informed of the nature of the study, is willing and able to comply with the protocol, and has provided written informed consent per Institutional Review Board (IRB) requirements

Exclusion Criteria:

  • Single episode, transient, or reversible AF (for example, secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)
  • Stroke or transient ischemic attack within 90 days before the index procedure
  • Myocardial infarction or unstable angina within 90 days before the index procedure
  • Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) less than (<)30 milliliters per minute (mL/min)/1.73 sqaure meter (m^2), or dialysis at the time of screening
  • Active infection with bacteremia
  • Confirmed coronavirus disease 2019 (COVID-19) infection within 10 days before the index procedure Coexisting Cardiovascular Disease
  • Cardiac tumor
  • History of mitral valve or other severe cardiac valvular disease requiring intervention or presence of prosthetic mechanical valve
  • Medical condition (other than AF) that mandates chronic oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or mechanical heart valve)
  • Severe heart failure (New York Heart Association Class IV)
  • Symptomatic carotid artery disease (greater than [>] 50 percent [%] diameter reduction with prior ipsilateral stroke or transient ischemic attack [TIA]) or asymptomatic carotid artery disease (diameter reduction of >70%) Previous or Planned Interventions
  • Previous AF ablation procedure in the 90 days before the index procedure date or need for AF ablation to be performed in less than 90 days after the index procedure
  • Recent (within 30 days before the index procedure) or planned (within 60 days after the index procedure) cardiac or non-cardiac interventional or surgical procedure
  • Intracardiac thrombus or dense spontaneous echo contrast visualized by transesophageal echocardiographic (TEE) within 2 days before the index procedure
  • Left ventricular ejection fraction (LVEF) <30%
  • Circumferential pericardial effusion >10 mm or symptomatic pericardial effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade physiology
  • Complex atheroma with mobile plaque of the aorta
  • Interatrial communication, atrial septal defect, or patent foramen ovale that warrants closure
  • Vascular access precluding delivery of implant with catheter-based system
  • Presence of inferior vena cava (IVC) filter that would interfere with Laminar sheath insertion
  • Participant unable to undergo general anesthesia
  • Participant with condition which precludes adequate TEE assessment
  • Known allergy, hypersensitivity or contraindication to aspirin, heparin, or device materials (e.g., nickel, titanium)
  • Contrast sensitivity that cannot be adequately pre-medicated
  • Thrombocytopenia , thrombocytosis, or leukopenia values as specified in protocol
  • Pregnant or nursing and those who plan pregnancy in the period up to 1 year following the index procedure. Participants of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days before index procedure
  • Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 1 year
  • Current participation in another investigational drug or device study that in the opinion of the investigator could confound the data interpretation

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment

Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure system.

Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Composite Adverse Events
Tidsramme: 45 days

Composite rate of all-cause mortality, stroke, systemic embolism, life threatening or major bleeding (BARC Type 3 or 5), pericardial effusion requiring drainage, device embolization, and device- or procedure-related events requiring open cardiac surgery or major endovascular intervention.

45 days
Composite Adverse Events
Tidsramme: 12 months

Composite rate of all-cause mortality, stroke, systemic embolism, life threatening or major bleeding (BARC Type 3 or 5), pericardial effusion requiring drainage, device embolization, and device- or procedure-related events requiring open cardiac surgery or major endovascular intervention.

12 months
LAA Closure Rate
Tidsramme: 45 days

Rate of LAA closure defined by peri-device flow ≤ 3mm in width per TEE evaluated by independent core laboratory.

45 days
LAA Closure Rate
Tidsramme: 12 months

Rate of LAA closure defined by peri-device flow ≤ 3mm in width per TEE evaluated by independent core laboratory.

12 months
LAA Closure Rate
Tidsramme: 45 days

Rate of LAA closure per CCTA evaluated by independent core laboratory. Contrast patency defined as LAA density ≥100 HU or ≥25% of that of the left atrium.

45 days
Composite of Ischemic Stroke or System Embolism
Tidsramme: 12 months

Composite of ischemic stroke or systemic embolism.

12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Device-Related Thrombus
Tidsramme: 45 days

Rate of device-related thrombus (DRT) per CCTA evaluated by independent core laboratory.

45 days
Device-Related Thrombus
Tidsramme: 12 months

Rate of DRT per TEE evaluated by independent core laboratory.

12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Biosense Webster, Inc. Clinical Trial, Biosense Webster, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. oktober 2022

Primær færdiggørelse (Faktiske)

7. august 2024

Studieafslutning (Anslået)

9. september 2028

Datoer for studieregistrering

Først indsendt

29. september 2022

Først indsendt, der opfyldte QC-kriterier

3. oktober 2022

Først opslået (Faktiske)

4. oktober 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CL0043
  • LAM202404 (Anden identifikator: Biosense Webster, Inc.)
  • CL0043 (Anden identifikator: Laminar, Inc.)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner